Panelists discuss how the novel antibody-drug conjugate PYX-201 targets the tumor microenvironment rather than cancer cells directly, showing promising early results in patients with head and neck squamous cell carcinoma for whom standard treatments, including immunotherapy, had failed, with patient Andrew Dunning sharing his experience of achieving complete remission after just 4 infusions while maintaining quality of life through fitness and community support.
